ATE358178T1 - Modulierung der tnf-rezeptoraktivität - Google Patents

Modulierung der tnf-rezeptoraktivität

Info

Publication number
ATE358178T1
ATE358178T1 AT93106981T AT93106981T ATE358178T1 AT E358178 T1 ATE358178 T1 AT E358178T1 AT 93106981 T AT93106981 T AT 93106981T AT 93106981 T AT93106981 T AT 93106981T AT E358178 T1 ATE358178 T1 AT E358178T1
Authority
AT
Austria
Prior art keywords
tnf
modulation
receptor activity
tnf receptor
peptides
Prior art date
Application number
AT93106981T
Other languages
English (en)
Inventor
David Wallach
Cord Brakebusch
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE358178T1 publication Critical patent/ATE358178T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93106981T 1992-05-03 1993-04-29 Modulierung der tnf-rezeptoraktivität ATE358178T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL101769A IL101769A (en) 1992-05-03 1992-05-03 Modulation of TNF receptor action

Publications (1)

Publication Number Publication Date
ATE358178T1 true ATE358178T1 (de) 2007-04-15

Family

ID=11063598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93106981T ATE358178T1 (de) 1992-05-03 1993-04-29 Modulierung der tnf-rezeptoraktivität

Country Status (8)

Country Link
US (4) US6395267B1 (de)
EP (2) EP0568925B1 (de)
JP (2) JP3712746B2 (de)
AT (1) ATE358178T1 (de)
DE (1) DE69334129T2 (de)
DK (1) DK0568925T3 (de)
ES (1) ES2281070T3 (de)
IL (1) IL101769A (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US20030054402A1 (en) 1993-03-31 2003-03-20 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US6864060B1 (en) 1993-03-31 2005-03-08 Cadus Technologies, Inc. Yeast cells expressing modified G proteins and methods of use therefor
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US7235648B1 (en) 1993-03-31 2007-06-26 Cadus Technologies, Inc. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
IL107268A0 (en) * 1993-10-12 1994-01-25 Yeda Res & Dev Molecules influencing the shedding of the tnf receptor, their preparation and their use
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
CA2184631A1 (en) * 1994-03-17 1995-09-21 John C. Cambier Product and process for regulating signal transduction pathways
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US6355780B1 (en) 1995-02-22 2002-03-12 Yeda Research And Development Co. Ltd. Antibodies to the death domain motifs of regulatory proteins
JP3860608B2 (ja) * 1995-02-22 2006-12-20 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 調節タンパク質のモジュレーター
IL114461A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev TNF modulation
EP0960196A4 (de) * 1996-10-04 2002-10-29 Immunex Corp Zelltod verursachender rezeptor
NZ335864A (en) 1996-11-06 2001-09-28 Univ California Isolated tumor necrosis factor receptor releasing enzyme (TRRE), compositions comprising the enzyme and methods of the use in modulation of TNF levels
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
US6355473B1 (en) 1998-05-06 2002-03-12 Cadus Pharmaceutical Corp. Yeast cells having mutations in stp22 and uses therefor
US7081360B2 (en) 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
US7273747B2 (en) 1998-08-27 2007-09-25 Cadus Technologies, Inc. Cell having amplified signal transduction pathway responses and uses therefor
US6251605B1 (en) 1998-10-27 2001-06-26 Cadus Pharmaceutical Corporation Yeast cells having mutations in Cav1 and uses therefor
AU2030000A (en) 1998-11-25 2000-06-13 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
IL132105A0 (en) * 1998-12-24 2001-03-19 Yeda Res & Dev Caspase-8 interacting proteins
US6504008B1 (en) 1999-02-01 2003-01-07 Cadus Technologies, Inc. Cell based signal generation
US6555325B1 (en) 1999-06-14 2003-04-29 Cadus Technologies, Inc. System for detection of a functional interaction between a compound and a cellular signal transduction component
US7223533B2 (en) 1999-09-10 2007-05-29 Cadus Technologies, Inc. Cell surface proteins and use thereof as indicators of activation of cellular signal transduction pathways
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1460088A1 (de) 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
CA2526690C (en) 2003-05-23 2014-01-14 Board Of Regents The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
AU2009224690B2 (en) 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
PL2262838T3 (pl) 2008-03-13 2016-10-31 Środek do leczenia choroby
CN102027017A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
WO2011049350A2 (ko) * 2009-10-19 2011-04-28 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
DK2657252T3 (en) * 2010-12-23 2017-05-08 Hanall Biopharma Co Ltd MODIFIED HUMAN TUMOR CANCER FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF AND METHOD OF PRODUCING THEREOF
DE102013223589B4 (de) 2013-11-19 2016-11-17 Hydrogenious Technologies Gmbh Anlage und Verfahren zum Speichern von Energie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
DK0393438T3 (da) * 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE4006269A1 (de) * 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action

Also Published As

Publication number Publication date
JP2004340975A (ja) 2004-12-02
JP3683263B2 (ja) 2005-08-17
US7429379B2 (en) 2008-09-30
US20020142357A1 (en) 2002-10-03
DE69334129T2 (de) 2007-12-13
IL101769A (en) 2007-02-11
IL101769A0 (en) 1992-12-30
EP0568925A3 (de) 1995-03-15
EP0568925A2 (de) 1993-11-10
US20060210560A1 (en) 2006-09-21
US6395267B1 (en) 2002-05-28
DK0568925T3 (da) 2007-05-29
JP3712746B2 (ja) 2005-11-02
EP1512697A1 (de) 2005-03-09
US20090088558A1 (en) 2009-04-02
JPH06233684A (ja) 1994-08-23
ES2281070T3 (es) 2007-09-16
DE69334129D1 (de) 2007-05-10
US7728111B2 (en) 2010-06-01
US7056505B2 (en) 2006-06-06
EP0568925B1 (de) 2007-03-28

Similar Documents

Publication Publication Date Title
DE69334129D1 (de) Modulierung der TNF-Rezeptoraktivität
ATE228534T1 (de) Struktur höherer ordnung und bindung von peptidnukleinsäuren
EP0670730A4 (de) Fusionsprotein, das dem rezeptor des tumornekrose-faktors enthält.
DK0964874T3 (da) CAML-bindende lymfocytoverfladereceptor, nukleinsyrer, som koder derfor, og fremgangsmåder til anvendelse deraf
FI894626L (fi) Komponentteja ja katalysaattoreita olefiinien polymerointia varten
DK0759067T3 (da) Transformerende vækstfaktor alfa-H1
AU6803790A (en) Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
EA200000311A1 (ru) Новый белок иммунной системы - кау
DE69404401D1 (de) Erythropoietin-Analoga mit zusätzlichen Glycosylierungsstellen
DE68927523D1 (de) Modifikation der Domäne der Konstantregion der Antikörpern
ATE380875T1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
PT2042509E (pt) Moduladores da função de recetores de fas e outras proteínas
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
GR3036782T3 (en) Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
DE68900381D1 (de) Gallosilikat-katalysator und dessen verwendung fuer die aromatisierung von c2-c4-leichten gasen.
DE68906566D1 (de) Dimerisierung von niedrigen alpha-olefinen.
DE68923636D1 (de) Halbleiter-Treiber zur Erzeugung von Schalt- und Offset-Signalen.
DE68918759D1 (de) Schalter mit einem "NCAP" Flüssigkristall.
AU617982B2 (en) Polypeptides of the rhinovirus strain HRV89 and the DNA molecules coding therefor
AU7574394A (en) TNF inhibitors
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
AU7117687A (en) Combination therapy using interleukin-2 and tumor necrosis factor
BG109537A (en) FUNCTION MODULATORS OF RECEPTORS OF TNF / NGF RECIPE FAMILY AND OTHER PROTEINS
DK0606869T3 (da) Promotorsekvens for p55-receptoren for tumornekrosefaktor
DE68920562D1 (de) Isomerisierung von Carbonsäuren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0568925

Country of ref document: EP